Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

CompletedOBSERVATIONAL
Enrollment

436

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

August 6, 2025

Study Completion Date

August 6, 2025

Conditions
Primary Ciliary DyskinesiaPrimary Immune DeficiencyKartagener Syndrome
Interventions
DIAGNOSTIC_TEST

Genetic Testing for PCD or PID

Patients with high likelihood of a PID disorder or a high likelihood of PCD will initially undergo research genetic testing on a commercial approved panel for PID disorders or a panel of at least 37 PCD genes.

OTHER

Unaffected Family Member Genetic Testing

Unaffected family members will undergo genetic testing if genetic findings are identified in their affected family member.

Trial Locations (8)

20814

National Heart, Lung and Blood Institute, Bethesda

27599

University of North Carolina at Chapel Hill, Chapel Hill

63130

Washington University in St. Louis, St Louis

80045

Children's Hospital Colorado, Aurora

94304

Stanford University, Palo Alto

98105

Seattle Children's Hospital, Seattle

M5G 0A4

The Hospital for Sick Children, Toronto

H4A 3J1

McGill University, Montreal

All Listed Sponsors
collaborator

Washington University School of Medicine

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Children's Hospital Colorado

OTHER

collaborator

Stanford University

OTHER

collaborator

Seattle Children's Hospital

OTHER

collaborator

The Hospital for Sick Children

OTHER

collaborator

McGill University

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT04702243 - Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults | Biotech Hunter | Biotech Hunter